Compare Braze Inc (BRZE) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Braze Inc vs Recursion Pharmaceuticals Inc — how do they compare? Braze Inc trades at $28.06 (market cap $3.18B), while Recursion Pharmaceuticals Inc trades at $3.36 (market cap $1.81B). The key difference: Braze Inc is the larger of the two by market cap, and Braze Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| BRZE | RXRX | |
|---|---|---|
Market Cap | $3.18B | $1.81B |
Sector | Technology | Health |
52-Week High | $36.19 | $6.79 |
52-Week Low | $15.79 | $2.84 |
Enterprise Value | $2.87B | $1.33B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Braze Inc
Braze Inc is a customer engagement platform that powers customer-centric interactions between consumers and brands. The company provides solutions for Retail & E-commerce, Media & Entertainment, Financial Services, and Travel & Hospitality related industries.
Read more on BRZE →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
